Literature DB >> 22385553

Low-density lipoprotein apheresis is effective in reducing lipoprotein(a) levels and in improving symptoms in a patient with refractory angina secondary to accelerated coronary artery disease.

Michael Ibrahim1, Bassey Ussen, Alison Pottle, Mahmoud Barbir.   

Abstract

Coronary artery disease remains a significant cause of morbidity and mortality in the Western world. High plasma Lp(a) concentrations are related to the risk of cardiovascular disease, but Lp(a) is rarely assayed and treated. We present the case of a 50-year-old gentleman with refractory angina, whose coronary disease continued to progress despite optimal medical and surgical therapy. We show that the aggressive reduction of Lp(a) successfully ameliorated the progression of coronary stenosis and provides effective and durable relief of symptoms. Copyright Â
© 2012 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22385553     DOI: 10.1016/j.jacl.2011.11.003

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  2 in total

1.  Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial.

Authors:  Tina Z Khan; Li-Yueh Hsu; Andrew E Arai; Samantha Rhodes; Alison Pottle; Ricardo Wage; Winston Banya; Peter D Gatehouse; Shivraman Giri; Peter Collins; Dudley J Pennell; Mahmoud Barbir
Journal:  Eur Heart J       Date:  2017-05-21       Impact factor: 29.983

Review 2.  The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina.

Authors:  Tina Z Khan; Alison Pottle; Dudley J Pennell; Mahmoud S Barbir
Journal:  Glob Cardiol Sci Pract       Date:  2014-01-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.